CC
ITOS

Corton Capital’s iTeos Therapeutics ITOS Stock Holding History

Corton Capital’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,332
Closed -$208K – 500
2024
Q3 		$208K Buy
+20,332
New +$310K 0.1% 357
2024
Q1 		– Sell
-12,152
Closed -$133K – 590
2023
Q4 		$133K Buy
+12,152
New +$120K 0.04% 528
2022
Q2 		– Sell
-10,820
Closed -$348K – 424
2022
Q1 		$348K Sell
10,820
-16,557
-60% -$602K 0.15% 186
2021
Q4 		$1.27M Buy
+27,377
New +$911K 0.57% 16

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Corton Capital's ITOS Position: Q4 2024 in Review

Corton Capital sold out of iTeos Therapeutics (ITOS) in Q4 2024, closing a stake of 20,332 shares — an estimated $208K sold.

Corton Capital first reported a position in ITOS in Q4 2021 and held it in 4 quarters. The position peaked at $1.27M in Q4 2021. 136 funds tracked by Wall St. Rank hold ITOS as of Q4 2024.

  • Corton Capital reported no remaining iTeos Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Corton Capital sold 20,332 iTeos Therapeutics shares in Q4 2024, an estimated $208K.
  • Corton Capital first reported a position in iTeos Therapeutics in Q4 2021 and held it in 4 quarters.
  • Corton Capital's iTeos Therapeutics position peaked at $1.27M in Q4 2021.
  • 136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2024.

Based on Corton Capital's 13F filing for Q4 2024, filed 14 Feb 2025.